Back to Search
Start Over
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
- Source :
-
PloS one [PLoS One] 2012; Vol. 7 (4), pp. e35843. Date of Electronic Publication: 2012 Apr 25. - Publication Year :
- 2012
-
Abstract
- Background and Objectives: Natalizumab reduces the relapse rate and magnetic resonance imaging activity in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). So far the influence of natalizumab on cognitive functions and fatigue in MS remains uncertain. The aim of this prospective, open-label, observational study was to evaluate the possible effects of natalizumab on cognition and fatigue measures in RRMS patients treated for up to two years.<br />Methods: Cognitive performances were examined by the Rao's Brief Repeatable Battery (BRB), the Stroop test (ST) and the Cognitive Impairment Index (CII), every 12 months. Patients who failed in at least 3 tests of the BRB and the ST were classified as cognitively impaired (CI). Fatigue Severity Scale (FSS) was administered every 12 months to assess patient's self-reported fatigue. One hundred and 53 patients completed 1 and 2 year-natalizumab treatment, respectively.<br />Results: After 1 year of treatment the percentage of CI patients decreased from 29% (29/100) at baseline to 19% (19/100) (pā=ā0.031) and the mean baseline values of CII (13.52±6.85) and FSS (4.01±1.63) scores were significantly reduced (10.48±7.12, p<0.0001 and 3.61±1.56, pā=ā0.008). These significant effects were confirmed in the subgroup of patients treated up to two years.<br />Conclusions: These results demonstrate that a short-term NTZ treatment may significantly improve cognitive performances and fatigue in RRMS patients.
- Subjects :
- Adult
Antibodies, Monoclonal, Humanized administration & dosage
Cognition drug effects
Drug Administration Schedule
Fatigue physiopathology
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting physiopathology
Multiple Sclerosis, Relapsing-Remitting psychology
Natalizumab
Neuropsychological Tests
Prospective Studies
Recurrence
Severity of Illness Index
Antibodies, Monoclonal, Humanized therapeutic use
Fatigue drug therapy
Multiple Sclerosis, Relapsing-Remitting drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 7
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 22558238
- Full Text :
- https://doi.org/10.1371/journal.pone.0035843